Dr. Kenneth Blum, B.Sc. (Pharmacy), M.Sc., PhD, DHL- received his PhD in Neuropharmacology from New York Medical College and is a graduate from Columbia University and New Jersey College of Medicine. He trained at the Institute of Behavioral Genetics, Colorado University at Boulder, Colorado. He also received a doctor of humane letters from St Martins University. He has published over 500 abstracts, peer– reviewed articles and books (16). He has been the recipient of many grants and awards including a Life-Time Achievement in Addiction Medicine (Holistic Institute on Addiction Studies); Marquis Who Who’s Life –Time Achievement Award, and Presidential Award for Scientific Excellence (National Council of Alcohol & Drug Abuse Councilors), Scientific Achievement Award (City of Life Miami) and Best Abstract (2012) Award ASRA (Pain); Path Foundation Lifetime Achievement Award (2014) and Honorary Full Professor (Eötvös Loránd University, Institute of Psychology, Budapest, Hungary) and American Society of Addiction Medicine Millennium Laboratory Award among many others. He coined the term “Reward Deficiency Syndrome “in 1995 now in Microsoft Dictionary, Gates Scientific dictionary and featured in SAGE Encyclopedia of Abnormal Psychology (2017). Currently he serves as Editor-in-chief of Journal of Reward Deficiency Syndrome & Addiction Science (Editor-in-chief), Co-EIC Neuroimaging in Psychiatry & Neurology, and is on the editorial board of 18 other scientific journals. As the lead author on the first genetic association of a dopaminergic gene with severe alcoholism, he is considered by some as the “Father of Psychiatric Genetics”. He is the holder of many U.S. and foreign patents involving nutrigenomics. He is the lead author of a new Springer Neuroscience Brief book on the 12 Steps -entitled “Molecular Neurobiology of Addiction Recovery.” Dr. Blum along with Mark Gold (St. Louis) and Philip Gorwood (Paris) has been named Editor-In Chief of Frontiers of Bioscience Special Issue on Reward Deficiency Syndrome (RDS). Dr. Blum is an adjunct Professor, in both the Department of Psychiatry at University of Florida College of Medicine and McKnight Brain Institute and the University of Vermont. He is Adjunct Full Professor in the Department of Psychiatry & Behavioral Science, Keck School of Medicine, University of Southern California and Adjunct Full Professor in the Department of Psychiatry, Wright University Boonshoft School of Medicine, Dayton, Ohio. He also serves as Neuroscience advisor to many companies and foundations including Dominion Diagnostics (Chief Scientific Adviser), Path Foundation NY (Director of Science), Victory Nutrition, Impact Genomics, Shores Treatment & Recovery Center (Neuroscience Advisor) and Nupathways. He currently serves as Chairman of the board of Geneus Health, San Antonio, Texas. He is Emeritus Faculty of The Institute of Applied Genomics and Biotechnology, Nagpur, India. Major media outlets worldwide have covered his work on addiction. He is currently serving as President and CEO of IGENE, LLC, Austin Texas and Founding President United Science Group (USG). Dr. Blum is working on the first ever Genetic Addiction Risk Score (GARS) in conjunction with Geneus Health and Dominion Diagnostics. He is a frequent contributor to Sober World and Addiction Professional magazines. In conjunction with Merlene Miller and David Miller they just published their award winning book “Staying Clean and Sober”. He is a sought after speaker on a global basis for insights into RDS and genetics. He has published in almost every major peer review journal in the world including Science, Nature, Lancet, JAMA, JAMA Psychiatry, PNAS, Plus One, Oncotarget, Cureus, psychopharmacology, molecular neurobiology, amongst many prestigious journals. His work has been featured in every major newspaper, magazine and television worldwide. He is indeed the father of Amino-Acid Therapy for Reward Deficiency Syndrome developing Pro –Dopamine Regulation to induce “dopamine Homeostasis “coupled with genetic testing for Personalized Addiction Medicine.
Kenneth Blum, PhD, DHL
Department of Psychiatry, Western University College of Medicine, Pomona, CA, USA
Founding Honorary Board
Dr. Marc Potenza is a board-certified Psychiatrist with sub-specialty training and certification in addiction psychiatry. He has trained at Yale University receiving a combined BS/MS with Honors in Molecular Biochemistry and Biophysics and a PhD in Cell Biology, the latter concurrent with the MD through the Medical Scientist Training Program. He completed internship, psychiatric residency and addiction psychiatry fellowship training at Yale. Currently, he is a Professor of Psychiatry, Child Study and Neurobiology at the Yale University School of Medicine where he is Director of the Problem Gambling Clinic, the Center of Excellence in Gambling Research, and the Women and Addictive Disorders Core of Women's Health Research at Yale. He is on the editorial boards of ten journals (including editor-in-chief of Current Addiction Reports) and has received multiple national and international awards for excellence in research and clinical care. He has consulted to the Substance Abuse and Mental Health Services Administration, National Registry of Effective Programs, National Institutes of Health, American Psychiatric Association and World Health Organization on matters of addiction. He has participated in two DSM-5 research work groups, addressing topics relating to gambling, impulse control, and addiction. Dr. Potenza's research has focused on the neurobiology and treatment of substance and non-substance addictions and other disorders characterized by impaired impulse control and reward-related motivations. The majority of this work has focused on understanding clinical and neurobiological underpinnings of these disorders, and their co-occurrences with other mental health disorders, in order to advance prevention and treatment strategies. Dr. Potenza's research has applied brain imaging, genetic, epidemiological and clinical trials methodologies to gain knowledge and improve prevention and treatment strategies for addictive disorders. This work has also involved identifying potential intermediary phenotypes, like facets of impulsivity, that may in part explain the high rates of co-occurrence between psychiatric conditions and might represent novel targets for prevention and treatment strategies.
Marc Potenza, MD, PhD
Yale University, USA
Non-Substance or Behavioral Addictions
David E. Smith, MD
University of California at San Francisco, USA
Adolescent Addiction
Dual Diagnosis
Process Addictions
Dr. Philip Gorwood studied medicine from 1982-1988, and specialised in psychiatry in 1988. He is currently full Professor of Psychiatry at Sainte-Anne Hospital and Head of the CMME department [Clinique des Maladies Mentales et de L’Encéphale, with 60 beds], teaching at the Paris-Descartes University. He is also Head of the Team 1 at INSERM (Institut National de la Santé et de la Recherche MEdical) research unit 894 (Center of Psychiatry and Neuroscience) devoted to genetic vulnerability of psychiatric and addictive disorders. Professor Gorwood has published over 200 scientific articles (h-index=42) and 24 book chapters. He has served on 16 editorial boards for journals in psychiatry, neuroscience and genetics, and is editor-in-chief of the journal European Psychiatry (IF=3.2) and responsible for the Progress in mind: Focus on Alcohol Use Disorders Resource Centre developed by Elsevier. He is now treasurer and member of the Core Organising and Scientific Committee (COSC), Executive Committee (EC) and board of the European Psychiatric Association. He joined the scientific advisory (SAB) board of the ECNP for addictive disorders in 2009. In 1992, Professor Gorwood received the Lilly ‘First Communication’ award and later in 1997, the French Association for Biological Psychiatry ‘Best Communication of the Year’ award. In 1999, he received the Association of European Psychiatry ‘Young Researcher’ award; and in 2000 the French National Academy of Medicine for the best research.
Philip Gorwood, MD, PhD
Paris Descartes University, France
Eating Disorder
Dr. Horace Loh, a graduate of National Taiwan University, earned his Ph.D. in biochemistry in 1965 from the University of Iowa and completed a postdoctoral fellowship in the Department of Pharmacology at the University of California, San Francisco in 1967. He later joined their faculty in the Departments of Psychiatry and Pharmacology. Twenty years into a successful career at the UCSF Medical Center, Dr. Loh accepted the headship of the Department of Pharmacology at the University of Minnesota in 1989. The year following his appointment as Head of Pharmacology, he was named Frederick and Alice Stark Professor in Neuroscience by the Medical School. In 2010, he was named a Regents Professor at the University of Minnesota- the highest honor the University can bestow to its faculty members. Dr. Loh has published over 500 original research papers and has trained approximately 30 Ph.D. students and 100 postdoctoral fellows. He has received several major awards in his field, including, most recently, the Founder’s Lecture Award from the International Narcotics Research Conference (2007); the University of Iowa Carver College of Medicine’s Distinguished Alumni Award for Achievement (2007); the Nathan B. Eddy Award for Lifetime Achievement in Drug Dependence Research from the College on Problems of Drug Dependence (2002); the Otto Krayer Award from the American Society for Pharmacology and Experimental Therapeutics (ASPET) (1999), and the Pharmaceutical Research and Manufacturers of American (PhRMA) Foundation Award in Excellence for Basic Pharmacology (1999).
Horace Loh, PhD
University of Minnesota, USA
Opiates and Opioids
Drug Addiction
Drug Tolerance
Drug Dependency
Dr. Tomas Palomo, MD by the Complutense University of Madrid in 1971, PhD in neuroanatomy by the University of Valladolid in 1974. In 1971 his university activity begins as assistant professor of Neuroanatomy at Valladolid Medical School and since then has led multidisciplinary clinical-preclinical investigation groups studying the cerebral basis of psychiatric disorders in Spain and the United Kingdom. From 1976 to 1978 in MRC Brain Metabolism Unit at Edinburgh he works on the molecular basis of Schizophrenia using animal models of dopamine supersensitivity. From 1980 to 1984 in Aberdeen University he develops animal models for the study of schizophrenia, depression and addictive disorders. From 1979 he is Lecturer of Psychiatry in the Universities of Newcastle (1979-1980), Aberdeen (1980-1984) and from 1985 to the present, professor of Psychiatry in the Complutense University of Madrid, Spain. From 1990 head of Psychiatry Department of “University Hospital 12 of October” of Madrid, he organized a Mental Health Services Network to attend Area 11 of Madrid with 900,000 inhabitants and created a base of clinical and biological investigation. At “University Hospital 12 of October” he set up the Unit for the investigation and treatment of addictive disorders (1995), organizes a research group for the study of schizophrenia with neuroimaging techniques (1996), a Unit for basic experimental neuropsychopharmacology (1998) and the Unit for genetic studies (2002). His main research interest is the dopaminergic system and its involvement in schizopsychotic and addictive disorders, and, in relation to these, of personality disorders and impulsivity. At present he is the national coordinator of the schizophrenia programme of CIBERSAM (National Spanish Research Net for Biomedical Research in Mental Disorders) and member of its executive committee. He was the Director of the Official School of Psychiatry from 1989 to 2004, and President of the Natonal Commission of Psychiatry in Spain from 1995 to 2006. Since he started research, clinical and teaching activities in 1971 he has been very active in promoting multidisciplinary clinical-basic research in Spain. In 1993 he founded the Fundacion Cerebro y Mente, multidisciplinary non-profit organization dedicated to the promotion and development of basic and applied neurosciences. He has organized 29 national and international scientific congresses in Spain on neuroscientific advances and their relevance to psychiatry, and has published over 200 scientific publications. He is editor of the national series of books “Avances Neurocientíficos y Realidad Clinical” (10 volumes) and the international series: “Strategies for Studying Brain Disorders” (11 volumes). At present he is in Madrid as Professor of Psychiatry in the Complutense University of Madrid; Coordinator of Neurosciences Research and President of the Scientific Committee at “University Hospital 12 of October” and “Institute i+12”; Head of Group 19 of CIBERSAM; and he is also President of the Foundation Cerebro y Mente.
Tomas Palomo, MD, PhD
Universidad Complutense de Madrid, Spain
Clinical Psychiatry
Associate Editorial Board
Dr. Jhodie Duncan is currently working in the field of addiction neuroscience investigating the long-term effects of inhalant abuse, a world-wide problem of growing socioeconomic concern especially for adolescent and Indigenous populations. After being awarded her PhD in Developmental Neuroscience from the University of Melbourne in 2002, she received a CJ Martin Fellowship to work with Professor Hannah Kinney at Harvard/Children’s Hospital Boston investigating the relationship between maternal cigarette smoking and Sudden Infant Death Syndrome (SIDS). She continues to perform an advocacy role in this field and serves as the Australian Scientific Coordinator on 2 international projects investigating Sudden and Unexpected Death in Pediatrics. In 2009 Dr Duncan took up a position with Professor Andrew Lawrence at the Florey developing a rodent model of adolescent inhalant misuse. In 2010 she was awarded an ARC Future Fellowship to continue this work, being promoted to Senior Research Fellow and Lab Head at the Florey within the last year. Her team is currently characterizing the long-term effects of adolescent inhalant abuse on behavior, relating these changes to pathalogical, neurochemical, epigenetic and metabolic changes in the brain and peripheral organs to better understand the mechanisms mediating inhalant-induced dysfunction. She currently has 37 publications and her work has been recognized through avenues including award of a First Candle/SIDS Alliance Fellowship and The Queen’s Trust For Young Australian’s.
Jhodie Duncan, PhD
University of Melbourne, Australia
Inhalant Abuse
Subhash Pandey, PhD
University of Illinois at Chicago, USA
Neurobiology of Alcoholism
Signaling Mechanism
Gene Expression
David Baron is currently Professor and Vice Chair, and Chief of Psychiatry at University Hospital at the Keck School of Medicine, University of Southern California. Dr. Baron is also the Director of the Global Center for Exercise, Psychiatry and Sport at USC and Chairman of the Section on Exercise, Psychiatry and Sport for the World Psychiatric Association/World Health Organization. He is also a current member of the Executive Board of Directors for the International Society of Sports Psychiatrists and the 2010 Consumer Council of America "Top Doc" for Sport Psychiatry. Dr. Baron is the former Deputy Clinical Director of the National Institute of Mental Health and Chair of the Department Psychiatry at the NIH graduate school 1989-1997 and Temple University (1998-2010). He developed, and holds the copyright on the only validated depression screener specifical for athletes (BDSA), which is currently in use in over 7 countries. He has over 30 years of clinical experience in sports medicine and sports psychiatry and has worked with athletes of all ages and levels of competition including NCAA, Olympic, and professional. He has published over 130 peer reviewed publications and presented over 300 scientific presentations in the US and over 30 invited international talks, many in the area of Doping in Sports and Depression, Drug Use and Concussion in athletes. His current clinical and research interests are in the neuropsychiatric sequel of recurrent sub-clinical concussion and TBI in athletes, specifically focused on developing more sensitive, user-friendly screening instruments and methods, and increasing public awareness of this growing problem.
David Baron, DO, MSEd
Keck School of Medicine of USC, USA
Global MH Public Literacy
Neuropsych aspects of Repetitive mTBI
Dr. Jag Khalsa, with about 50 years of experience in drug research, serves as the Chief of the Medical Consequences Branch, National Institute on Drug Abuse, NIH, DHHS; is responsible for developing/administering a national and international program of clinical research on medical and health consequences of drug abuse and co-occurring infections (HIV, HCV, and others). Prior to joining NIDA in 1987, he served for ~10 yrs as a pharmacologist/toxicologist assessing safety (carcinogenic/teratogenic) potential of chemicals [INDs/NDAs] and food additives) and clinical evaluator at FDA. He has published in pharmacology, toxicology, epidemiology and medical journals. He serves on editorial boards of Journals of Addiction Medicine, Research on HIV/AIDS and Palliative Care, Frontiers of Neuroscience, and Clinical Infectious Diseases. He also serves on numerous Federal and NIH level committees including the HHS Viral Hepatitis Implementation Group (VHIG), National Commission on Digestive Diseases and its two sub-committees (Liver Research, Diabetes Research), Federal Task Force on TB, NIH Steering Committee on Centers for AIDS Research, and Human Microbiome Workgroup. He has received distinguished service awards from the FDA Commissioner, NIDA and NIH Directors, Society of Neuro-Immune-Pharmacology (SNIP), Life Time Achievement Awards from SNIP and International Conference on Molecular Medicine (India) and MIT, India; a commendation from the US Congress, Awards of Merit from the International Society of Addiction Medicine (ISAM), the President of the American Society of Addiction Medicine (ASAM), and a Certificate of Appreciation from the Office of Assistant Secretary for Health (Drs. Howard Koh and Ron Valdiserri), DHHS. He has a PhD in neuro-psycho-pharmacology, a Master’s degree in herbal pharmacology, post-doctoral training in CNS/Cardiovascular pharmacology at SK&F, and Toxicology at SRI International.
Jag Khalsa, MS, PhD
National Institute on Drug Abuse, USA
Drug Abuse
Subject Editors
Wayne Westcott, PhD
Quincy College, USA
Strength Training Protocols
Health-Related effects of Resistance Exercise
Dr. Anish Bajaj has practiced Chiropractic in New York City since 2001 with a focus on wellness and integrative healthcare strategies. Following graduation from State University of New York at Geneseo, Dr. Bajaj pursued his Doctor of Chiropractic from Life University in Atlanta Georgia. He has been the Director of Neuromuscular, Skeletal and Vascular Diagnostics at world renowned brain anti-aging center, Path Medical, for the past 13 years and has served as their Executive Health Program Director since 2006. As a clinician Dr. Bajaj specializes in Sacro-Occiptal-Technique, Soft Tissue Orthopedics, Sports Chiropractic, Electro-Therapeutics and Spinal Stabilizing Foot Orthotics. He served on the Executive Board of the New York Chiropractic Council from 2008 to 2010 as the President of the Manhattan District. He co-founded the American Decompression Pro Chiropractors which introduced the patented Neuro-Oxy Spinal Decompression Technique. His research in the fields of electrotherapeutics and cognitive function correlations to bone metabolism has been published in peer-reviewed journals including BMC Endocrine Disorders. He has also authored articles on integrative care, extremity adjusting/sports chiropractic, and the advancement of chiropractic neurology. As an Anti-Aging expert Dr. Bajaj has served as Instructor for the American Academy of Anti-Aging Medicine and has lectured around the U.S. as well as in Paris, Singapore and Beijing as a guest of the World Congress on Anti-Aging. Dr Bajaj is currently working on advancement of EEG data utilization in research, clinician support and patient education applications.
Anish Bajaj, DC
Path Medical Clinics, USA
Heart Rate Variablity
Functional Neurology
Dr Schoenthaler J. Schoenthaler received his MA in sociology from Syracuse University in 1975 and his PhD in sociology from the State University of New York at Buffalo in 1980 with specializations in criminology and deviant behavior. He joined the faculty at California State University, Stanislaus in Turlock, California in 1982, developed its criminal justice major in 1983, was promoted to Associate Professor in 1985, and Professor in 1990. He was the 2nd Professor at Stanislaus to be awarded the “Outstanding Researcher and Creative Professor Award in 2001 and the Linus Pauling Ortho molecular Award for Outstanding Research the same year. These were due to his research on nutrition and human behavior that proceeded over three phases. From 1980 to 1984, he was the principal investigator in 14 open trials in 917 educational or correctional institutions. Each showed that when nutrition of children better matched the recommendations of the National Academy of Sciences Food and Nutrition Board for fruits, vegetables, and whole grains by limiting sweets and fats, academic success rose significantly and juvenile delinquency fell over 40% in New York, Virginia, Alabama, and California. In 1985, he led research teams in New York, California, Virginia and Oklahoma that conducted 7-day dietary analyses of incarcerated offenders and found that, in each state, those at high risk of being malnourished were significantly more likely to commit serious incidents such as assault and battery than those who were at low risk of being malnourished with differences reaching over 30%. His research also showed that malnutrition in correctional institutions was widespread due to many offenders avoiding essential food groups at meals or only consuming food from other sources. From 1986 until today, Professor Schoenthaler has been leading research teams in conducting parallel randomized controlled trials in Oklahoma, California, and Arizona on the effects of vitamins and minerals versus placebo on crime, delinquency, violence, verbal and non-verbal IQ, academic performance, brain function, and biochemical changes in blood among schoolchildren (elementary, junior high, and high school), incarcerated delinquents, and incarcerated adult felons. In each well-controlled randomized trial, participants in the correctional system given active tablets produced significantly less crime and delinquency (28 to 41%) and often normalized blood chemistry and brain function. Among schoolchildren on active tablets, school suspensions fell 47% more than controls while both non-verbal intelligence and academic performance rose significantly. Three English and Dutch research teams have successfully replicated these findings among both schoolchildren and confined felons. Professor Schoenthaler has created over 150 peer reviewed publications, grants, and/or professional publications.
Stephen J. Schoenthaler, PhD
California State University, USA
Biosocial Criminology
Brain Function
Dr. Thomas McLaughlin was born in Staten Island, NY and studied at St. Peter’s Prep, a Jesuit high school, in Jersey City. He received his BA at St. Peter’s College, with a major in Psychology and a minor in Philosophy. Dr. McLaughlin spent the following year as a Fulbright Scholar at the Johannes Gutenberg University, in Mainz, Germany. Following this, he received an NIMH Fellowship to study Clinical Psychology at Boston University, where he received his M.A. and Ph.D. degrees. Dr. McLaughlin doctoral dissertation involved the use of Feedback Electroencephalography to study Attention in Schizophrenic patients. Following these studies, he worked as a Clinical Psychologist for four years and, then, entered the New Jersey College of Medicine, from which he obtained my M.D. in 1980. Dr. McLaughlin internship was done at the Hackensack University Medical Center. Following this, he did a Neurology Residency at Boston University. After my neurological training, he entered the Psychiatry Residency Program at McLean Hospital, a Harvard Teaching Hospital, in Belmont MA, where he served as a Teaching Fellow as well. Since becoming separately Board-Certified in both Neurology and Psychiatry, he have practiced out-patient Psychiatry, while also carrying out rCBF/SPECT brain-imaging research at the laboratory of Professor Niels Lassen in Copenhagen.. Dr. Mclaughlin first became aware of “Reward Deficiency Syndrome” seven years ago and his clinical work has been informed by its findings and theory. Dr. McLaughlin currently applies it to the diagnosis and treatment of Tourette’s syndrome, ADHD, and Substance-Dependent patients.
Thomas McLaughlin, MD
Center For Psychiatric Medicine, Massachusetts, USA
Tourette's Syndrome
Limbic Dis-Inhibition
Substance Dependence
Dr. Csaba Barta is currently an Assistant Professor at the Institute of Medical Chemistry, Molecular Biology and Pathobiochemisry at Semmelweis University, Budapest, Hungary. He joined the Laboratory of Molecular Genetics as a graduate medical student and later defended his Ph.D. theses on the analysis, genotyping and prenatal diagnosis of monogenic disorders. Earlier he implemented genetic screening of steroid 21-hydroxylase deficiency in Hungary and also applied it for the first prenatal diagnosis case of congenital adrenal hyperplasia in the country. He was also working on the detection of point mutations in the plasma cholinesterase (BCHE) gene in children with complications during anesthesia and in their families. Apart from these studies he was involved in our investigations concerning methodological advances in genotyping, as well. As a molecular geneticist his main research interest shifted to the field of psychiatric genetics. Since 2001 he has been responsible for genetic association studies of the dopamine and the serotonin systems in several clinical populations, such as substance dependence (mainly heroine, alcohol and nicotine), Tourette’s syndrome, ADHD, etc. He is involved in a number of large international collaborations, eg. the European Network for the Study of Gilles de la Tourette Syndrome (COST Action BM0905) and TS-Eurotrain: Interdisciplinary training network for Tourette Syndrome (FP7-PEOPLE-2012-Marie Curie ITN), as well as the International Consortium on ADHD and Substance Abuse (ICASA). He also takes part in the biochemistry tutoring of medical students in the Hungarian, English and German programs of Semmelweis University.
Csaba Barta, MD, PhD
Semmelweis University, Hungary
Psychiatric Genetics
Substance Dependence
Tourette’s Syndrome
Dr. Adriaan Bruijnzeel is an Associate Professor in the Department of Psychiatry at the University of Florida. He received his PhD in Neuroscience from Utrecht University (The Netherlands) and then did a postdoc in the Department of Neuropharmacology at the Scripps Research Institute in San Diego (USA). The Bruijnzeel-lab is located in the McKnight Brain Institute at the University of Florida and studies the neurobiology underlying nicotine, alcohol, and cannabis dependence. Our research suggests that a dysregulation of brain stress systems contributes to the brain reward deficit associated with drug withdrawal and stress-induced reinstatement of drug seeking. The studies point to a critical role of stress peptides such as corticotropin-releasing factor, alpha-melanocyte stimulating hormone (α-MSH), and vasopressin in nicotine withdrawal and relapse. In addition to this, our laboratory has investigated the effects of tobacco smoke, opioids, and alcohol on brain reward function and characterized the behavioral effects of tobacco and cannabis smoke. Dr. Bruijnzeel has received grant support from the National Institutes of Health (NIH), Flight Attendant Medical Research Institute (FAMRI), and the James and Esther King Biomedical Research Program. He has served as grant reviewer for the NIH, Italian Ministry of Health, National Science Center (Poland), Canadian Tobacco Control Research Initiative, Michael Smith Foundation for Health Research (Canada), Canadian Institutes of Health Research (Canada), and the Medical Research Council (United Kingdom).
Adriaan W. Bruijnzeel, PhD
University of Florida, USA
Cannabis Withdrawal
Drug-Self Administration
Stress-Induced Reinstatement
AAV Vectors
Bernard William (Bill) Downs
Victory Nutrition International Inc., USA
Biological Chemistry
Behavioral Biology
RDS Spectrum Disorders
Chronic Degenerative Diseases
Carolyn Coker Ross, MD, MPH
The Recovery Village at Palmer Lake - a subsidiary of Advanced Recovery Systems, USA
Eating Disorders
Integrative Medicine
Alcohol and Drug Dependence
Mood Disorders